메뉴 건너뛰기




Volumn 86, Issue 14, 2012, Pages 7588-7595

The development of CD4 binding site antibodies during HIV-1 infection

(20)  Lynch, Rebecca M a   Tran, Lillian a   Louder, Mark K a   Schmidt, Stephen D a   Cohen, Myron c   DerSimonian, Rebecca a   Euler, Zelda g   Gray, Elin S d,e   Karim, Salim Abdool f   Kirchherr, Jennifer b   Montefiori, David C b   Sibeko, Sengeziwe f   Soderberg, Kelly b   Tomaras, Georgia a   Yang, Zhi Yong a   Nabel, Gary J a   Schuitemaker, Hanneke g   Morris, Lynn d,e   Haynes, Barton F b   Mascola, John R a  


Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; CORE PROTEIN; EPITOPE; GLYCOPROTEIN GP 120; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY VRC CH31; NEUTRALIZING ANTIBODY VRC PG04; NEUTRALIZING ANTIBODY VRC01; RESURFACED STABILIZED CORE PROTEIN; UNCLASSIFIED DRUG;

EID: 84863769888     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00734-12     Document Type: Article
Times cited : (112)

References (45)
  • 1
    • 0026655937 scopus 로고
    • Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro
    • Barbas CF, III, et al. 1992. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. U. S. A. 89:9339-9343.
    • (1992) Proc. Natl. Acad. Sci. U. S. A. , vol.89 , pp. 9339-9343
    • Barbas III, C.F.1
  • 2
    • 56449131391 scopus 로고    scopus 로고
    • Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
    • Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
    • (2008) J. Virol. , vol.82 , pp. 11651-11668
    • Binley, J.M.1
  • 3
    • 80052938385 scopus 로고    scopus 로고
    • Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors
    • Bonsignori M, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009.
    • (2011) J. Virol. , vol.85 , pp. 9998-10009
    • Bonsignori, M.1
  • 4
    • 84860723906 scopus 로고    scopus 로고
    • Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design
    • Bonsignori M, et al. 2012. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86:4688-4692.
    • (2012) J. Virol. , vol.86 , pp. 4688-4692
    • Bonsignori, M.1
  • 5
    • 0027985431 scopus 로고
    • Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
    • Burton DR, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
    • (1994) Science , vol.266 , pp. 1024-1027
    • Burton, D.R.1
  • 6
    • 13844255333 scopus 로고    scopus 로고
    • Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41
    • Cardoso RM, et al. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
    • (2005) Immunity , vol.22 , pp. 163-173
    • Cardoso, R.M.1
  • 7
    • 77649318846 scopus 로고    scopus 로고
    • Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
    • doi:10.1371/journal-.pone.0008805
    • Corti D, et al. 2010. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 5:e8805. doi:10.1371/journal-.pone.0008805.
    • (2010) PLoS One , vol.5
    • Corti, D.1
  • 8
    • 67249085575 scopus 로고    scopus 로고
    • Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site
    • doi:10.1371/journal.ppat.1000445
    • Dey B, et al. 2009. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5:e1000445. doi:10.1371/journal.ppat.1000445.
    • (2009) PLoS Pathog , vol.5
    • Dey, B.1
  • 9
    • 82755184131 scopus 로고    scopus 로고
    • Increasing the potency and breadth of an HIV antibody by using structure-based rational design
    • Diskin R, et al. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289-1293.
    • (2011) Science , vol.334 , pp. 1289-1293
    • Diskin, R.1
  • 10
    • 77749306129 scopus 로고    scopus 로고
    • Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression
    • Euler Z, et al. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201:1045-1053.
    • (2010) J. Infect. Dis. , vol.201 , pp. 1045-1053
    • Euler, Z.1
  • 11
    • 0041828179 scopus 로고    scopus 로고
    • Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    • Fiebig EW, et al. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871-1879.
    • (2003) AIDS , vol.17 , pp. 1871-1879
    • Fiebig, E.W.1
  • 12
    • 67449147145 scopus 로고    scopus 로고
    • The first T cell response to transmitted/ founder virus contributes to the control of acute viremia in HIV-1 infection
    • Goonetilleke N, et al. 2009. The first T cell response to transmitted/ founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253-1272.
    • (2009) J. Exp. Med. , vol.206 , pp. 1253-1272
    • Goonetilleke, N.1
  • 13
    • 79955389756 scopus 로고    scopus 로고
    • The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+T cell decline and high viral load during acute infection
    • Gray ES, et al. 2011. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840.
    • (2011) J. Virol. , vol.85 , pp. 4828-4840
    • Gray, E.S.1
  • 14
    • 69249208675 scopus 로고    scopus 로고
    • Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors
    • Gray ES, et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83:8925-8937.
    • (2009) J. Virol. , vol.83 , pp. 8925-8937
    • Gray, E.S.1
  • 15
    • 0034482696 scopus 로고    scopus 로고
    • Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates
    • Kwong PD, et al. 2000. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8:1329-1339.
    • (2000) Structure , vol.8 , pp. 1329-1339
    • Kwong, P.D.1
  • 16
    • 34948854718 scopus 로고    scopus 로고
    • Broad HIV-1 neutralization mediated by CD4-binding site antibodies
    • Li Y, et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034.
    • (2007) Nat. Med. , vol.13 , pp. 1032-1034
    • Li, Y.1
  • 17
    • 58149517700 scopus 로고    scopus 로고
    • Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    • Li Y, et al. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83:1045-1059.
    • (2009) J. Virol. , vol.83 , pp. 1045-1059
    • Li, Y.1
  • 18
    • 80055115342 scopus 로고    scopus 로고
    • Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection
    • Liu P, et al. 2011. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J. Virol. 85:11196-11207.
    • (2011) J. Virol. , vol.85 , pp. 11196-11207
    • Liu, P.1
  • 19
    • 83455254775 scopus 로고    scopus 로고
    • Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
    • McLellan JS, et al. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343.
    • (2011) Nature , vol.480 , pp. 336-343
    • McLellan, J.S.1
  • 21
    • 79551518897 scopus 로고    scopus 로고
    • Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    • doi:10.1371/ journal.ppat.1001251
    • Mikell I, et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251. doi:10.1371/ journal.ppat.1001251.
    • (2011) PLoS Pathog , vol.7
    • Mikell, I.1
  • 22
    • 0027397052 scopus 로고
    • Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans
    • Moore JP, Ho DD. 1993. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67:863-875.
    • (1993) J. Virol. , vol.67 , pp. 863-875
    • Moore, J.P.1    Ho, D.D.2
  • 23
    • 80053584837 scopus 로고    scopus 로고
    • Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting
    • doi:10.1371/journal.pone.0023532
    • Morris L, et al. 2011. Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One 6:e23532. doi:10.1371/journal.pone.0023532.
    • (2011) PLoS One , vol.6
    • Morris, L.1
  • 24
    • 4544379899 scopus 로고    scopus 로고
    • Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
    • Ofek G, et al. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:10724-10737.
    • (2004) J. Virol. , vol.78 , pp. 10724-10737
    • Ofek, G.1
  • 25
    • 82255179322 scopus 로고    scopus 로고
    • A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield
    • Pejchal R, et al. 2011. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334:1097-1103.
    • (2011) Science , vol.334 , pp. 1097-1103
    • Pejchal, R.1
  • 26
    • 70349298392 scopus 로고    scopus 로고
    • Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression
    • Piantadosi A, et al. 2009. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83:10269-10274.
    • (2009) J. Virol. , vol.83 , pp. 10269-10274
    • Piantadosi, A.1
  • 28
    • 58149487645 scopus 로고    scopus 로고
    • Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection
    • Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
    • (2009) J. Virol. , vol.83 , pp. 757-769
    • Sather, D.N.1
  • 29
    • 80052925616 scopus 로고    scopus 로고
    • Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    • Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
    • (2011) Science , vol.333 , pp. 1633-1637
    • Scheid, J.F.1
  • 30
    • 0027256814 scopus 로고
    • Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
    • Thali M, et al. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67:3978-3988.
    • (1993) J. Virol. , vol.67 , pp. 3978-3988
    • Thali, M.1
  • 31
    • 0026085170 scopus 로고
    • Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody
    • Thali M, et al. 1991. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody. J. Virol. 65:6188-6193.
    • (1991) J. Virol. , vol.65 , pp. 6188-6193
    • Thali, M.1
  • 32
    • 80055104586 scopus 로고    scopus 로고
    • Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals
    • Tomaras GD, et al. 2011. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85:11502-11519.
    • (2011) J. Virol. , vol.85 , pp. 11502-11519
    • Tomaras, G.D.1
  • 33
    • 57349127300 scopus 로고    scopus 로고
    • Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia
    • Tomaras GD, et al. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82:12449-12463.
    • (2008) J. Virol. , vol.82 , pp. 12449-12463
    • Tomaras, G.D.1
  • 34
    • 9044241681 scopus 로고    scopus 로고
    • Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    • Trkola A, et al. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
    • (1996) J. Virol. , vol.70 , pp. 1100-1108
    • Trkola, A.1
  • 35
    • 80053132436 scopus 로고    scopus 로고
    • Broad neutralization coverage of HIV by multiple highly potent antibodies
    • Walker LM, et al. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470.
    • (2011) Nature , vol.477 , pp. 466-470
    • Walker, L.M.1
  • 36
    • 70349887757 scopus 로고    scopus 로고
    • Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    • Walker LM, et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
    • (2009) Science , vol.326 , pp. 285-289
    • Walker, L.M.1
  • 37
    • 77958115264 scopus 로고    scopus 로고
    • A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
    • doi:10.1371/journal.ppat.1001028
    • Walker LM, et al. 2010. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6:e1001028. doi:10.1371/journal.ppat.1001028.
    • (2010) PLoS Pathog , vol.6
    • Walker, L.M.1
  • 38
    • 0036090585 scopus 로고    scopus 로고
    • Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    • Wei X, et al. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
    • (2002) Antimicrob. Agents Chemother. , vol.46 , pp. 1896-1905
    • Wei, X.1
  • 39
    • 77954920017 scopus 로고    scopus 로고
    • Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    • Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
    • (2010) Science , vol.329 , pp. 856-861
    • Wu, X.1
  • 40
    • 70350320690 scopus 로고    scopus 로고
    • Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment
    • Wu X, et al. 2009. Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J. Virol. 83:10892-10907.
    • (2009) J. Virol. , vol.83 , pp. 10892-10907
    • Wu, X.1
  • 41
    • 80052942203 scopus 로고    scopus 로고
    • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    • Wu X, et al. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602.
    • (2011) Science , vol.333 , pp. 1593-1602
    • Wu, X.1
  • 42
    • 0032543555 scopus 로고    scopus 로고
    • The antigenic structure of the HIV gp120 envelope glycoprotein
    • Wyatt R, et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
    • (1998) Nature , vol.393 , pp. 705-711
    • Wyatt, R.1
  • 43
    • 10744226328 scopus 로고    scopus 로고
    • Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library
    • Zhang MY, et al. 2003. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J. Immunol. Methods 283:17-25.
    • (2003) J. Immunol. Methods , vol.283 , pp. 17-25
    • Zhang, M.Y.1
  • 44
    • 77954943648 scopus 로고    scopus 로고
    • Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    • Zhou T, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
    • (2010) Science , vol.329 , pp. 811-817
    • Zhou, T.1
  • 45
    • 33847101745 scopus 로고    scopus 로고
    • Structural definition of a conserved neutralization epitope on HIV-1 gp120
    • Zhou T, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
    • (2007) Nature , vol.445 , pp. 732-737
    • Zhou, T.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.